Single Center Experience With Hyperthermic Intraperitoneal Chemotherapy

Area of Science:

• Surgical Oncology
• Gastroenterology
• Cancer Metastasis

Background:

• Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are proposed for peritoneal metastasis.
• Their safety and efficacy, particularly for colorectal cancers, remain under investigation.

Purpose of the Study:

• To present early experiences with CRS and HIPEC procedures.
• To analyze short-term outcomes and identify risk factors for postoperative complications.

Main Methods:

• Retrospective data collection from patients with peritoneal carcinomatosis (PC) and pseudomyxoma peritonei (PMP).
• Patients underwent CRS and HIPEC between July 2014 and July 2015.
• Analysis of short-term outcomes and risk factors for complications.

Main Results:

• 23 patients (18 PC, 5 PMP) underwent CRS and HIPEC.
• 78.3% achieved CC0-1 status.
• Grade-III complications occurred in 30.4% of patients; no 30-day mortality.
• Factors for complications included organ resection number, operation time, and blood loss.

Conclusions:

• Initial CRS and HIPEC experience showed approximately 30% grade-III postoperative complications.
• These procedures require careful execution by expert surgeons in carefully selected patients.